BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Merrick VM, Mortier K, Williams LJ, Muhammed R, Auth MK, Elawad M, Fell JM, Beattie RM, Loganathan S, Torrente F, Morris M, Charlton C, Croft NM, Rodrigues A, Furman M, Vadamalayan B, Jenkins H, Zamvar V, Mitton SG, Chong S, Cosgrove M, Akobeng A, Wilson DC, Russell RK. Real-life Anti-tumor Necrosis Factor Experience in More Than 500 Patients: High Co-immunosuppression Rates But Low Rates of Quantifying Treatment Response. Journal of Pediatric Gastroenterology & Nutrition 2018;66:274-80. [DOI: 10.1097/mpg.0000000000001679] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Clarkston K, Tsai YT, Jackson K, Rosen MJ, Denson LA, Minar P. Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients. J Pediatr Gastroenterol Nutr 2019;69:68-74. [PMID: 31232885 DOI: 10.1097/MPG.0000000000002304] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 9.5] [Reference Citation Analysis]
2 Bramuzzo M, Arrigo S, Romano C, Filardi MC, Lionetti P, Agrusti A, Dipasquale V, Paci M, Zuin G, Aloi M, Strisciuglio C, Miele E, Pastore M, Martelossi S, Alvisi P; SIGENP IBD Working Group. Efficacy and safety of infliximab in very early onset inflammatory bowel disease: a national comparative retrospective study. United European Gastroenterol J 2019;7:759-66. [PMID: 31316780 DOI: 10.1177/2050640619847592] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]